孟鲁司特钠用于急性发作期支气管哮喘患儿的临床效果及对CD4+ CD8+及CD4+/CD8+水平的影响

doi:10.3969/j.issn.1006-6233.2019.01.008

摘要
图/表
参考文献
相关文章 (11)

全文: PDF (1210 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨孟鲁司特钠用于急性发作期支气管哮喘患儿的临床效果及对CD₄⁺、CD₈⁺及CD₄⁺/CD₈⁺水平的影响。方法:选择2015年6月至2018年6月我院接诊的76例急性发作期支气管哮喘患儿,采用随机数字表法分为观察组和对照组,各38例。对照组患儿给予常规吸氧、补液等治疗措施,观察组患儿在此基础上给予孟鲁司特钠进行治疗。比较两组治疗前后CD₄⁺、CD₈⁺及CD₄⁺/CD₈⁺水平、用力肺活量(FVC)、最大呼气峰流速(PEF)及第1秒用力呼气容积(FEV1)、症状评分的变化及症状改善时间。结果:治疗后,观察组CD₄⁺、CD₄⁺/CD₈⁺水平均显著高于对照组[(39.25±7.15)%vs(32.87±6.38)%,(1.89±0.53)vs(1.37±0.54)](P<0.05),CD₈⁺水平明显低于对照组[(25.06±8.04)% vs(30.54±6.26)%](P<0.05);观察组FVC、PEF及FEV1均高于对照组[(79.24±7.11)% vs(68.48±5.26)%,(1.40±0.44)L/s vs(1.17±0.34)L/s,(76.55±3.55)% vs(65.85±3.46)%](P<0.05);观察组症状缓解用时及体征消失用时均低于对照组[(3.34±0.75)d vs(5.64±1.05)d ,(5.22±1.17)d vs(7.62±1.55)d](P<0.05);观察组患儿日间症状评分及夜间症状评分均低于对照组[(1.12±0.45)分 vs(1.63±0.58)分,(1.16±0.46)分 vs(2.03±0.75)分](P<0.05)。结论:给予急性发作期支气管哮喘患儿常规治疗的基础上,加以孟鲁司特钠进行治疗可有效改善患儿的免疫功能、肺功能,缩短治疗用时,疗效显著。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈亮
	林元涛
	周洪玉

关键词 ：孟鲁司特钠, 支气管哮喘, 免疫指标

Abstract：Objective: To explore the clinical effect of montelukast sodium in children with acute attack of bronchial asthma and its influence on CD₄⁺, CD₈⁺ and CD₄⁺/CD₈⁺ levels. Methods: 76 children with acute attack of bronchial asthma in our hospital from June 2015 to June 2018 were selected and randomly divided into observation group and control group, 38 cases in each group. The control group was treated with routine oxygen inhalation and fluid replacement, while the observation group was treated with montelukast sodium. The levels of CD₄⁺, CD₈⁺, CD₄⁺/CD₈⁺, forced vital capacity (FVC), peak expiratory flow (PEF), forced expiratory volume (FEV1), changes of symptom score and improvement time of symptoms were compared between the two groups before and after treatment. Results:After treatment, the levels of CD₄⁺, CD₄⁺ /CD₈⁺ in the immune function of the observation group were significantly higher than those of the control group [(39.25±7.15)% vs (32.87±6.38)%, (1.89±0.53) vs (1.37±0.54)] (P<0.05), and the level of CD₈⁺ was significantly lower than that of the control group [(25.06±8.04)% vs (30.54±6.26)%] (P<0.05); The FVC, PEF and FEV1 in the observation group were higher than those in the control group [(79.24±7.11)% vs (68.48±5.26)%,(1.40±0.44)L/s vs (1.17±0.34)L/s, (76.55±3.55)% vs (65.85±3.46)%] (P<0.05); The symptom relief, time and signs disappeared in the observation group, all lower than those in the control group [(3.34±0.75)d vs (5.64±1.05)d, (5.22±1.17)d vs (7.62±1.55)d] (P<0.05); The daily symptom score and night symptom score of the observation group were lower than that of the control group [(1.12±0.45) score vs (1.63±0.58) score, (1.16±0.46) score vs (2.03±0.75) score] (P<0.05). Conclusion:On the basis of routine treatment for children with acute attack of bronchial asthma, montelukast sodium treatment can effectively improve the immune function and lung function of children, shorten the treatment time, and have a significant effect.

Key words： Montelukast sodium Bronchial asthma Immune index

基金资助:四川省卫生厅科研课题项目,(编号:120351)

引用本文:

陈亮, 林元涛, 周洪玉. 孟鲁司特钠用于急性发作期支气管哮喘患儿的临床效果及对CD₄⁺ CD₈⁺及CD₄⁺/CD₈⁺水平的影响[J]. 河北医学, 2019, 25(1): 30-33.
CHEN Liang, LIN Yuantao, ZHOU Hongyu. Montelukast Sodium in the Treatment of Children with Acute Attack of Bronchial Asthma and the effect on the CD₄⁺ CD₈⁺ and CD₄⁺/CD₈⁺ Levels. HeBei Med, 2019, 25(1): 30-33.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.01.008 或 http://www.hbyxzzs.cn/CN/Y2019/V25/I1/30